These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 31789011)
1. COLCOT and CANTOS: piecing together the puzzle of inflammation and cardiovascular events. Wohlford GF; Van Tassell BW; Ravindra K; Abbate A Minerva Cardioangiol; 2020 Feb; 68(1):5-8. PubMed ID: 31789011 [No Abstract] [Full Text] [Related]
4. [Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?]. Hoogeveen RM; Stroes ESG; Cornel JH Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201620 [TBL] [Abstract][Full Text] [Related]
5. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. Roman YM; Hernandez AV; White CM Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120 [TBL] [Abstract][Full Text] [Related]
6. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents? Ridker PM Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469 [No Abstract] [Full Text] [Related]
7. Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication? Whayne TF Am J Cardiovasc Drugs; 2021 Jan; 21(1):1-10. PubMed ID: 32356107 [TBL] [Abstract][Full Text] [Related]
8. Is colchicine a promising novel treatment option for cardiovascular medicine? Imazio M; Gaita F Heart; 2016 Apr; 102(8):569-70. PubMed ID: 26839067 [No Abstract] [Full Text] [Related]
9. Inflammation in atherosclerotic cardiovascular disease. Shah PK; Lecis D F1000Res; 2019; 8():. PubMed ID: 31448091 [TBL] [Abstract][Full Text] [Related]
10. Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval. Pascart T; Norberciak L; Ea HK; Graf S; Guggenbuhl P; Lioté F Rheumatology (Oxford); 2019 Dec; 58(12):2181-2187. PubMed ID: 31177284 [TBL] [Abstract][Full Text] [Related]
11. Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2). Samuel M; Tardif JC Future Cardiol; 2021 May; 17(3):411-414. PubMed ID: 33687270 [No Abstract] [Full Text] [Related]
16. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents. Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions. Mehta A; Mahtta D; Gulati M; Sperling LS; Blumenthal RS; Virani SS Curr Atheroscler Rep; 2020 Jan; 22(1):3. PubMed ID: 31927694 [TBL] [Abstract][Full Text] [Related]
18. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Nidorf SM; Thompson PL Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286 [TBL] [Abstract][Full Text] [Related]